Wall Street brokerages predict that Spero Therapeutics Inc (NASDAQ:SPRO) will report $1.38 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Spero Therapeutics’ earnings, with the highest sales estimate coming in at $2.50 million and the lowest estimate coming in at $400,000.00. Spero Therapeutics reported sales of $660,000.00 in the same quarter last year, which would suggest a positive year-over-year growth rate of 109.1%. The firm is scheduled to issue its next quarterly earnings report on Thursday, November 14th.
On average, analysts expect that Spero Therapeutics will report full year sales of $18.17 million for the current financial year, with estimates ranging from $13.62 million to $25.92 million. For the next year, analysts anticipate that the business will post sales of $10.29 million, with estimates ranging from $10.00 million to $10.60 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Spero Therapeutics had a negative net margin of 321.37% and a negative return on equity of 33.84%. The business had revenue of $2.16 million for the quarter, compared to analysts’ expectations of $6.95 million.
Large investors have recently made changes to their positions in the business. Acadian Asset Management LLC acquired a new stake in shares of Spero Therapeutics in the second quarter worth about $25,000. Marshall Wace LLP acquired a new stake in shares of Spero Therapeutics in the first quarter worth about $39,000. D.A. Davidson & CO. acquired a new stake in shares of Spero Therapeutics in the second quarter worth about $115,000. Virtu Financial LLC acquired a new stake in shares of Spero Therapeutics in the first quarter worth about $134,000. Finally, Wells Fargo & Company MN lifted its position in shares of Spero Therapeutics by 187.9% in the second quarter. Wells Fargo & Company MN now owns 13,660 shares of the company’s stock worth $157,000 after buying an additional 8,915 shares during the last quarter. 45.08% of the stock is owned by institutional investors.
Shares of SPRO stock traded up $0.22 on Friday, reaching $10.00. 4,147 shares of the company’s stock traded hands, compared to its average volume of 30,021. Spero Therapeutics has a 12-month low of $5.52 and a 12-month high of $14.48. The company has a debt-to-equity ratio of 0.04, a quick ratio of 13.66 and a current ratio of 13.66. The company has a market capitalization of $182.50 million, a P/E ratio of -3.85 and a beta of 2.08. The business’s 50 day moving average price is $10.29 and its two-hundred day moving average price is $11.52.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Featured Story: Gross Domestic Product (GDP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.